Ommelander Ziekenhuis Groningen B.V.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis2 trials
• Colorectal cancer1 trial
• Multiple myeloma1 trial
• Peripheral artery disease1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 33 trials
• Phase 43 trials

Status

• Recruiting3 trials
• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• Amsterdam UMC Stichting2 trials
• Leiden University Medical Center1 trial
• Radboud universitair medisch centrum Stichting1 trial
• Stichting Hemato-Oncologie voor Volwassenen Nederland1 trial
• The Netherlands Cancer Institute1 trial

Running trials

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Active, not recruiting

  Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

  NCT04225312· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Leiden University Medical Center· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  Personalized dosing of ocrelizumab in MS

  2024-513193-22-00· Phase 4· Amsterdam UMC Stichting· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Multiple myeloma1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  GENPAD

  NCT04619927· Phase 4· Radboud universitair medisch centrum Stichting· Source